To test this, we used 18F‐FP‐DTBZ PET imaging, a technique known for its high sensitivity, specificity, and affinity for VMAT2, to visualize and quantify monoaminergic denervation [23] and simultaneous fMRI, a widely used measurement of spontaneous blood‐oxygen‐level‐dependent neural activity, to assess disruptions in depression‐related brain networks at rest. The gene discussed is SLC18A2; the disease is depressive symptom measurement.